ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

BMC Geriatrics is a leading open-access journal dedicated to advancing the field of geriatrics and gerontology. Published by BMC, this esteemed journal has been at the forefront of research since its inception in 2001, providing a vital platform for sharing innovative studies and insights that address the complexities of aging. With an impressive Q1 ranking in the 2023 category of Geriatrics and Gerontology and a solid Scopus ranking at #40 out of 116, BMC Geriatrics showcases high-impact research that influences clinical practices and policy-making. As a fully open-access publication, it ensures that groundbreaking research is freely available to researchers, practitioners, and students alike, promoting the diffusion of knowledge across the global healthcare community. This journal is crucial for anyone interested in the latest developments in elderly care, health issues affecting aging populations, and innovative interventions designed to improve quality of life among older adults.

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

Geriatrics & Gerontology International, published by WILEY, is a prestigious academic journal dedicated to advancing the field of geriatric and gerontological research. With a strong focus on the interdisciplinary aspects of aging, this journal has established itself as a leading source of high-quality research, reflected in its impressive impact factor and 2023 Scopus rankings, including a Q1 status in Health (Social Science) and Q2 in both Geriatrics and Gerontology. Since its inception in 2004 and continuous publication from 2008 to 2024, it has fostered a vibrant exchange of ideas among researchers, clinicians, and students alike. The journal serves as a critical resource for innovative studies, reviews, and commentaries that help shape policies and practices affecting the elderly population. It is essential reading for those dedicated to improving the quality of life for older adults and contributes significantly to the understanding of the complexities surrounding aging.

Aging Medicine, published by Wiley, is a pivotal open-access journal that has been at the forefront of research dedicated to the aging population since its inception in 2018. With a focus on both geriatric care and gerontology, the journal serves as a crucial resource for researchers, healthcare professionals, and students interested in understanding the complexities of aging and the related medical challenges. Although it holds a Q3 quartile ranking in the fields of Aging and Geriatrics and Gerontology according to the 2023 metrics, the journal continues to effectively disseminate valuable research and insights, helping to bridge gaps in knowledge and practice. With an E-ISSN of 2475-0360, it offers an open-access model that ensures broader accessibility to its published content, thus promoting collaboration and innovation across disciplines. As the journal converges towards 2024, it remains committed to evolving with the dynamics of aging research, making it a significant platform for the exchange of ideas and advancements in this essential field.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, published by SAGE PUBLICATIONS LTD, is a pivotal resource in the fields of oncology, pharmacology, and medicine, with a dedicated focus on the evolving discipline of oncology pharmacy. Based in the United Kingdom, this journal has been diligently serving its readers since 1995 and continues to explore the intersection of pharmaceutical care and cancer treatment, showcasing innovative practices, research findings, and clinical advancements that are indispensable for healthcare professionals, researchers, and students alike. Although not an open-access journal, it holds a respectable Category Quartile Q3 ranking across its various fields, including Medicine, Oncology, and Pharmacology, indicating its relevance in nurturing academic discourse and addressing critical issues in cancer care. With an ISSN of 1078-1552 and E-ISSN of 1477-092X, the journal invites contributions that enhance the understanding of pharmaceutical interventions in oncology, aiming to improve therapeutic outcomes and patient care. Join a global community of professionals committed to excellence in oncology pharmacy practice and stay informed with cutting-edge research and reviews that significantly impact patient healthcare strategies.

Journal of Frailty & Aging, published by SPRINGER BASEL AG, is a leading platform dedicated to advancing research in the fields of aging, geriatrics, and gerontology. With an ISSN of 2260-1341 and an E-ISSN of 2273-4309, this journal has established itself as a pivotal resource for scholars and practitioners aiming to explore the complexities of frailty and its impact on aging populations. As of 2023, it proudly holds a Q3 classification in Aging and Q2 classifications in both Geriatrics and Gerontology, as well as Physiology (medical), alongside a notable Q1 ranking in Medicine (miscellaneous). The journal's Scopus ranks further reflect its quality and relevance, with rankings as high as #22 in Aging within the Biochemistry, Genetics and Molecular Biology category. The Journal of Frailty & Aging invites contributions that illuminate contemporary challenges and innovations in the field, offering Open Access to enhance the dissemination of knowledge. By publishing rigorous research and impactful reviews, the journal strives to foster a deeper understanding of health and well-being in older adults, making it an essential resource for researchers, healthcare professionals, and students engaged in this vital area of study.

Australian Prescriber is a distinguished open-access journal published by Therapeutic Guidelines Ltd, aiming to advance the field of pharmacology and medical prescriptions. Since its inception in 1994, this journal has been dedicated to disseminating essential findings and insights related to therapeutic guidelines and pharmaceutical care, making it an invaluable resource for healthcare professionals and researchers alike. With an ISSN of 0312-8008 and an E-ISSN of 1839-3942, it caters to an audience that values evidence-based medicine, empowering practitioners with knowledge to enhance clinical practice. The journal currently holds a Q2 ranking in the Pharmacology (medical) category and is recognized in the 51st percentile among its peers, reflecting its significant contributions to the medical field. Available from 1995 to 2024, this journal not only serves as an academic platform but also a critical discussion forum for professionals keen on improving pharmacological practices in Australia and beyond.